Eton Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference
23 Agosto 2023 - 12:50PM
Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative
pharmaceutical company focused on developing and commercializing
treatments for rare diseases, announced today that Sean Brynjelsen,
Chief Executive Officer, will present at the H.C. Wainwright 25th
Annual Global Investment Conference in New York City as follows:
Date: |
Wednesday,
September 13, 2023 |
|
|
Time: |
9:00am ET |
|
|
To schedule a 1x1 meeting with the Company, please contact
Corporate Access at H.C. Wainwright.
About Eton Pharmaceuticals
Eton is an innovative pharmaceutical company
focused on developing, acquiring, and commercializing innovative
products to address unmet needs in patients suffering from rare
diseases. The Company currently has three commercial rare disease
products, ALKINDI SPRINKLE® for the treatment of pediatric
adrenocortical insufficiency, Carglumic Acid for the treatment of
hyperammonemia due to N-acetylglutamate synthase (NAGS) deficiency,
and Betaine Anhydrous for the treatment of homocystinuria. The
Company has four additional product candidates in late-stage
development: dehydrated alcohol injection, which has received
Orphan Drug Designation for the treatment of methanol poisoning,
ZENEO® hydrocortisone autoinjector for the treatment of adrenal
crisis, ET-400 for the treatment of adrenocortical insufficiency,
and ET-600 for the treatment of diabetes insipidus. For more
information, please visit our website at www.etonpharma.com.
Investor Relations:Lisa M. Wilson, In-Site
Communications, Inc.T: 212-452-2793E: lwilson@insitecony.com
Source: Eton Pharmaceuticals.
Grafico Azioni Eton Pharmaceuticals (NASDAQ:ETON)
Storico
Da Apr 2024 a Mag 2024
Grafico Azioni Eton Pharmaceuticals (NASDAQ:ETON)
Storico
Da Mag 2023 a Mag 2024